Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. A gut-health scientist and chef eats fermented foods every day.

Cell therapy developer Arcellx contends its lead program could be a safer alternative to currently available CAR T-treatments for multiple myeloma, noting that its previously reported preliminary ...

I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of BCMA CAR-T therapies against Legend Biotech. Legend has downplayed the ...

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82. On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal ...

Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend ...

Arcellx, Inc. (NASDAQ:ACLX – Get Free Report)’s share price rose 5.1% on Wednesday after UBS Group raised their price target on the stock from $106.00 to $114.00.UBS Group currently has a buy ...

Arcellx's anito-cel shows 97% overall response rate and 62% CR/sCR rate in high-risk RRMM patients during Phase 2 iMMagine-1 trial. No severe neurotoxicities observed in over 150 patients dosed ...

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.57 billion, has been making waves in the cell therapy space with its innovative approach to treating multiple myeloma and ...

Arcellx stock reversed lower Monday despite positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. Please watch the video at Investors.com - How To Buy Stocks ...